Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Alpha BRAIN Nootropic Shows Statistical Significance In Groundbreaking Clinical Trial
  • USA - English


News provided by

Onnit

Jan 15, 2015, 09:00 ET

Share this article

Share toX

Share this article

Share toX


(PRWEB) January 15, 2015 -- Onnit Labs, an Austin based total human optimization company, recently announced a major milestone in their clinical research platform. The flagship Earth grown nutrient based nootropic Alpha BRAIN, which has already sold over 16 million capsules, released clinical trial results in a podcast with Dr. Todd Solomon of The Boston Center for Memory.

We put the reputation of our company on the line with this trial because we believe not only in the quality of product we provide, but the importance of unbiased empirical data.

Post this

In discussing the results of the study Dr. Todd Solomon commented “We are encouraged by the results” Dr. Solomon went on to clarify, “We are an independent research organization that has conducted over one hundred clinical trials in compounds for cognitive benefit and our goal was to apply the same rigorous scientific standards and methods in the study of Alpha BRAIN as we do in any other clinical trial. Our plan from the outset was to disseminate the data from the study, regardless of whether the study demonstrated any significant findings. As such, we are always encouraged by results that indicate a potential for benefit, however, as in any single clinical trial, the results will need to be replicated before any definitive conclusions can be made.”

The double blind, randomized, placebo controlled trial of over 60 patients showed clear statistical significance (p < .05) in the aspect of verbal memory after 6 weeks of supplementation. In a standardized test of verbal memory, subjects were prompted to memorize a list of unrelated words over several trials. When asked to recall words from the list roughly twenty minutes later, the Alpha BRAIN group, on average, recalled significantly more words as compared to their placebo counterparts.

In addition to a neurocognitive battery, a subset of subjects underwent an additional electroencephalogram (EEG) protocol to characterize notable brain wave frequencies, such as Alpha (8-15hz), Beta (16-31 Hz) and Theta (4-7 Hz). Peak alpha frequencies correlate positively with healthy cognition, attentiveness, and inhibition control. A compelling finding from the EEG data showed that subjects randomized to Alpha BRAIN supplementation had significantly higher peak alpha frequencies (p=0.0041). Another assessment tool of attentional vigilance is the ratio of theta/beta frequencies. The Alpha BRAIN group trended toward a significantly improved ratio (p=0.0551), an encouraging finding given the small sample size. These additional biomarkers not only help elucidate the mechanism of improved memory function, but also reveal the direct physiological changes that occur when taking Alpha BRAIN.

“This is the holy grail of clinical research for a natural supplement. To be able to show statistically significant improvement in healthy adults with a natural supplement is one of the most challenging things to do. We put the reputation of our company on the line with this trial because we believe not only in the quality of product we provide, but the importance of unbiased empirical data,” commented Aubrey Marcus, Onnit CEO.

This trial, which followed similar parameters of a successful pilot trial announced in Q4 2013 brings the total patient group to over 80 healthy individuals. In both trials Alpha BRAIN was well tolerated with minimal to no side effects. Notable amongst the side effects reported was an increase in vivid dreams, which is not uncommon with elevation of the neurotransmitter acetylcholine.

Commenting on Alpha BRAIN, Jarrett Leech, scientific advisor to Onnit added “The Alpha BRAIN formula was built on the shoulders of giants. The ingredients used all had sound clinical evidence of efficacy in some aspect of cognitive performance. What this study showed was that the whole can be greater than the sum of its parts.”

Key ingredients used in Alpha BRAIN include Huperzia Serrata, a traditional Chinese herb that has been shown to contain the acetylcholine enhancer Huperzine A, as well as AC-11®, a proprietary extract of the Amazon rainforest herb Uncaria Tomentosa licensed exclusively for use in nootropics from Optigenex Inc. Research on AC-11® has indicated the extract has an ability to help the body repair itself on a cellular level.

Medical advisor to Onnit, Dr. Dan Engle MD commented, “In my practice as a psychiatrist I have yet to come across a natural supplement with data as strong as Alpha BRAIN for healthy individuals. It begs the question, how effective might it be for those showing signs of age related cognitive decline?”

Onnit CEO Aubrey Marcus hinted that it would be interesting to study that indication directly, but plans to wait until publication of this initial trial is complete. The Boston Center for Memory has submitted the results for presentation to The American Academy of Neurology Conference in April of 2015 and will submit for publication in a major journal to follow soon after.

In line with Onnit’s philosophy of constant study and improvement of its product line, this is only the beginning. “The data from this trial has only just started to ripple out from our network of customers. Based on our overwhelming customer response to the Alpha BRAIN product, a great safety profile, the data on our ingredients, and the evidence from this study, the potential market size for this supplement is unlimited. We passionately believe in the case for human optimization, as we understand that often the tipping point between success and failure is simply performing to the best of your capability.”

For more information and further details on Alpha BRAIN and the study visit http://www.onnit.com

For questions on the study contact [email protected]
Media and other inquiries contact [email protected]

Jennifer Turner, Onnit, http://www.onnit.com, +1 855-666-4899, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.